Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis.

Cho Naing, Maxine A Whittaker, Victor Nyunt Wai, Joon Wah Mak
Author Information
  1. Cho Naing: School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
  2. Maxine A Whittaker: School of Population Health, University of Queensland, Brisbane, Australia.
  3. Victor Nyunt Wai: School of Medicine, International Medical University, Kuala Lumpur, Malaysia.
  4. Joon Wah Mak: School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.

Abstract

BACKGROUND: Plasmodium vivax is one of the major species of malaria infecting humans. Although emphasis on P. falciparum is appropriate, the burden of vivax malaria should be given due attention. This study aimed to synthesize the evidence on severe malaria in P. vivax infection compared with that in P. falciparum infection.
METHODS/PRINCIPAL FINDINGS: We searched relevant studies in electronic databases. The main outcomes required for inclusion in the review were mortality, severe malaria (SM) and severe anaemia (SA). The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale. Overall, 26 studies were included. The main meta-analysis was restricted to the high quality studies. Eight studies (n = 27490) compared the incidence of SM between P. vivax infection and P. falciparum mono-infection; a comparable incidence was found in infants (OR: 0.45, 95% CI:0.04-5.68, I2:98%), under 5 year age group (OR: 2.06, 95% CI: 0.83-5.1, I2:83%), the 5-15 year-age group (OR: 0.6, 95% CI: 0.31-1.16, I2:81%) and adults (OR: 0.83, 95% CI: 0.67-1.03, I2:25%). Six studies reported the incidences of SA in P. vivax infection and P. falciparum mono-infection; a comparable incidence of SA was found among infants (OR: 3.47, 95%:0.64-18.94, I2: 92%), the 5-15 year-age group (OR:0.71, 95% CI: 0.06-8.57, I2:82%). This was significantly lower in adults (OR:0.75, 95% CI: 0.62-0.92, I2:0%). Five studies (n = 71079) compared the mortality rate between vivax malaria and falciparum malaria. A lower rate of mortality was found in infants with vivax malaria (OR:0.61, 95% CI:0.5-0.76, I2:0%), while this was comparable in the 5-15 year- age group (OR: 0.43, 95% CI:0.06-2.91, I2:84%) and the children of unspecified-age group (OR: 0.77, 95% CI:0.59-1.01, I2:0%).
CONCLUSION: Overall, the present analysis identified that the incidence of SM in patients infected with P. vivax was considerable, indicating that P. vivax is a major cause of SM. Awareness of the clinical manifestations of vivax malaria should prompt early detection. Subsequent treatment and monitoring of complications can be life-saving.

References

  1. Ann Trop Paediatr. 2011;31(4):351-6 [PMID: 22041470]
  2. PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
  3. Ann Intern Med. 1987 Aug;107(2):224-33 [PMID: 3300460]
  4. Emerg Infect Dis. 2010 Oct;16(10):1611-4 [PMID: 20875292]
  5. N Engl J Med. 2009 Mar 19;360(12):1254; author reply 1255 [PMID: 19297580]
  6. Trends Parasitol. 2009 May;25(5):220-7 [PMID: 19349210]
  7. PLoS Med. 2008 Jun 17;5(6):e127 [PMID: 18563961]
  8. J Health Popul Nutr. 2012 Mar;30(1):113-6 [PMID: 22524128]
  9. PLoS Med. 2008 Jun 17;5(6):e128 [PMID: 18563962]
  10. Trends Parasitol. 2013 Dec;29(12):585-92 [PMID: 24210256]
  11. J Infect Dis. 2007 Feb 15;195(4):589-96 [PMID: 17230420]
  12. Am J Trop Med Hyg. 2007 Jun;76(6):997-1008 [PMID: 17556601]
  13. PLoS Med. 2012;9(9):e1001305 [PMID: 22973182]
  14. Pathog Glob Health. 2013 Jun;107(4):210-4 [PMID: 23816514]
  15. Vaccine. 2007 Jul 9;25(28):5115-23 [PMID: 17577487]
  16. BMC Public Health. 2013 Jul 08;13:637 [PMID: 23834734]
  17. MMWR Surveill Summ. 2013 Nov 1;62(5):1-17 [PMID: 24172939]
  18. J Clin Diagn Res. 2013 Sep;7(9):1964-7 [PMID: 24179910]
  19. Malar J. 2013 Dec 27;12:462 [PMID: 24370274]
  20. PLoS Med. 2013 Dec;10(12):e1001575; discussion e1001575 [PMID: 24358031]
  21. Malar J. 2012 Nov 28;11:395 [PMID: 23190709]
  22. Pathog Glob Health. 2013 Sep;107(6):299-304 [PMID: 24188240]
  23. Am J Trop Med Hyg. 2002 Nov;67(5):459-64 [PMID: 12479544]
  24. PLoS One. 2012;7(4):e35406 [PMID: 22523591]
  25. Clin Infect Dis. 2013 Feb;56(3):383-97 [PMID: 23087389]
  26. J Assoc Physicians India. 2012 Oct;60:15-8 [PMID: 23777019]
  27. Antimicrob Agents Chemother. 2004 Nov;48(11):4075-83 [PMID: 15504824]
  28. PLoS Negl Trop Dis. 2012;6(12):e1972 [PMID: 23272266]
  29. Am J Trop Med Hyg. 2012 Jul;87(1):41-49 [PMID: 22764290]
  30. Malar J. 2012 May 02;11:144 [PMID: 22551061]
  31. Am J Epidemiol. 1986 Dec;124(6):869-83 [PMID: 3776970]
  32. J Infect Dis. 2008 Nov 15;198(10):1558-64 [PMID: 18808339]
  33. Ann Trop Paediatr. 2009 Dec;29(4):253-6 [PMID: 19941747]
  34. J Infect Dev Ctries. 2013 Mar 14;7(3):273-9 [PMID: 23493007]
  35. Am J Trop Med Hyg. 2007 Nov;77(5):984-91 [PMID: 17984364]
  36. Ann Afr Med. 2013 Jul-Sep;12(3):155-9 [PMID: 24005587]
  37. Malar J. 2012 Apr 27;11:135 [PMID: 22540175]
  38. Clin Infect Dis. 2009 Jun 15;48(12):1704-12 [PMID: 19438395]
  39. Am J Trop Med Hyg. 2010 Nov;83(5):981-9 [PMID: 21036824]
  40. Malar J. 2012 Jan 09;11:12 [PMID: 22230294]
  41. PLoS Negl Trop Dis. 2010 Aug 03;4(8):e774 [PMID: 20689816]
  42. Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90 [PMID: 11103309]
  43. PLoS One. 2011;6(12):e29203 [PMID: 22216212]
  44. J Clin Diagn Res. 2013 Oct;7(10):2234-7 [PMID: 24298484]
  45. Trends Parasitol. 2007 Nov;23(11):533-9 [PMID: 17933585]
  46. Br J Vener Dis. 1933 Oct;9(4):219-29 [PMID: 21773526]
  47. Int J Parasitol. 2012 Nov;42(12):1099-105 [PMID: 23022617]
  48. Clin Microbiol Rev. 2013 Jan;26(1):36-57 [PMID: 23297258]
  49. Paediatr Int Child Health. 2012 Aug;32(3):152-7 [PMID: 22824663]
  50. PLoS Negl Trop Dis. 2011 Jun;5(6):e1160 [PMID: 21738804]
  51. Malar J. 2013 May 01;12:148 [PMID: 23634728]
  52. Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):67-72 [PMID: 23563828]
  53. Infect Chemother. 2013 Mar;45(1):69-75 [PMID: 24265952]
  54. Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87 [PMID: 18165478]
  55. Emerg Infect Dis. 2005 Jan;11(1):132-4 [PMID: 15705338]
  56. J Infect Dis. 2009 Feb 1;199(3):445-50 [PMID: 19090777]
  57. J Assoc Physicians India. 2012 Oct;60:11-3 [PMID: 23777018]
  58. Platelets. 2010;21(8):623-7 [PMID: 21050055]
  59. PLoS One. 2013 Jul 26;8(7):e69930 [PMID: 23922860]
  60. Clin Infect Dis. 2012 Oct;55(8):e67-74 [PMID: 22772803]
  61. Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62 [PMID: 9231189]
  62. Braz J Infect Dis. 2005 Oct;9(5):425-30 [PMID: 16410895]
  63. J Pediatr. 1996 Jun;128(6):791-6 [PMID: 8648538]
  64. Microbes Infect. 2004 May;6(6):572-8 [PMID: 15158191]
  65. Emerg Infect Dis. 2013 Nov;19(11):1851-4 [PMID: 24188313]
  66. Am J Trop Med Hyg. 2003 Apr;68(4):410-2 [PMID: 12875288]

MeSH Term

Adolescent
Adult
Anemia
Child
Child, Preschool
Chloroquine
Drug Resistance
Humans
Infant
Malaria, Falciparum
Malaria, Vivax
Respiratory Distress Syndrome

Chemicals

Chloroquine

Word Cloud

Created with Highcharts 10.0.0vivax0malariaP95%studiesOR:falciparumgroupCI:severeinfectionSMincidenceCI:0comparedmortalitySAcomparablefoundinfants5-15OR:0I2:0%PlasmodiummajormainreviewqualityincludedOverallmeta-analysisn=mono-infectionageyear-ageadultslowerrateBACKGROUND:onespeciesinfectinghumansAlthoughemphasisappropriateburdengivendueattentionstudyaimedsynthesizeevidenceMETHODS/PRINCIPALFINDINGS:searchedrelevantelectronicdatabasesoutcomesrequiredinclusionanaemiamethodologicalassessedusingNewcastle-OttawaScale26restrictedhighEight274904504-568I2:98%5year20683-51I2:83%631-116I2:81%8367-103I2:25%Sixreportedincidencesamong34795%:064-1894I2:92%7106-857I2:82%significantly7562-092Five71079615-076year-4306-291I2:84%childrenunspecified-age7759-101CONCLUSION:presentanalysisidentifiedpatientsinfectedconsiderableindicatingcauseAwarenessclinicalmanifestationspromptearlydetectionSubsequenttreatmentmonitoringcomplicationscanlife-savingmalaria?:systematic

Similar Articles

Cited By (89)